(Q34344140)

English

A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1 reference

based on heuristic

inferred from title

author name string

C M L van Herpen

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

F A L M Eskens

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

M de Jonge

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

I Desar

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

L Hooftman

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

E A Bone

6

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

J N H Timmer-Bonte

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

J Verweij

8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

0 references

publication date

28 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

103

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1362-1368

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990605

6 July 2018

CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990605

6 July 2018

Eosinophilic myocarditis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990605

6 July 2018

Albumin-bound paclitaxel: a next-generation taxane

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990605

6 July 2018

Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990605

6 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990605

6 July 2018

Hypersensitivity reactions from taxol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990605

6 July 2018

Randomized Double-Blind Placebo-Controlled Trial of Bestatin in Patients With Resected Stage I Squamous-Cell Lung Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605917

21 January 2018

Aminopeptidase inhibition as a targeted treatment strategy in myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605917

21 January 2018

Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990605

27 October 2018

Immunomodulatory and therapeutic properties of bestatin in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20877350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6605917

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34344140&oldid=2196528792"